Molybdenum Nanoparticles Alleviate Psoriasis-Related Cardiovascular Oxidative Stress and Inflammation

Psoriasis is a common immune-mediated chronic inflammatory disease, and its impact on patients extends beyond the skin. With the continuous deepening of understanding of psoriasis, the multisystem comorbidities of psoriasis have gradually been revealed. These comorbidities include cardiovascular diseases, metabolic diseases, liver and kidney diseases, autoimmune diseases, digestive system diseases, and mental disorders, etc. Among them, the cardiovascular comorbidities of psoriasis, as they can lead to fatal myocardial infarction and affect the survival rate of patients, deserve attention. Based on previous studies, this research further explores the effect of a molybdenum nanoparticle suspension (MNS) on psoriasis-related cardiovascular inflammation. The study found that the content of ROS in the cardiovascular tissues of psoriasis model mice, the infiltration of inflammatory cells, and the expression of inflammatory mediators (TNF-α, IFN-γ, IL-1β, IL-6, and IL-17) were significantly increased, and decreased after treatment with MNS. In addition, cardiomyocyte hypertrophy observed in the model group was alleviated following MNS intervention, and the ROS/NF-κB axis may be associated with psoriasis-related cardiovascular oxidative stress and inflammation.